GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Shiller PE Ratio

Macrogenics (Macrogenics) Shiller PE Ratio : (As of May. 11, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Macrogenics Shiller PE Ratio Historical Data

The historical data trend for Macrogenics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Shiller PE Ratio Chart

Macrogenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Macrogenics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Macrogenics's Shiller PE Ratio

For the Biotechnology subindustry, Macrogenics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Macrogenics's Shiller PE Ratio falls into.



Macrogenics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Macrogenics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Macrogenics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.75/129.4194*129.4194
=-0.750

Current CPI (Dec. 2023) = 129.4194.

Macrogenics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.120 99.695 -0.156
201406 -0.440 100.560 -0.566
201409 -0.140 100.428 -0.180
201412 -0.690 99.070 -0.901
201503 1.420 99.621 1.845
201506 -0.710 100.684 -0.913
201509 -0.460 100.392 -0.593
201512 -0.900 99.792 -1.167
201603 -0.880 100.470 -1.134
201606 1.120 101.688 1.425
201609 -0.970 101.861 -1.232
201612 -1.000 101.863 -1.271
201703 -1.080 102.862 -1.359
201706 -1.140 103.349 -1.428
201709 -1.280 104.136 -1.591
201712 2.960 104.011 3.683
201803 -1.340 105.290 -1.647
201806 -1.030 106.317 -1.254
201809 -0.810 106.507 -0.984
201812 -1.060 105.998 -1.294
201903 -0.990 107.251 -1.195
201906 -0.650 108.070 -0.778
201909 -0.910 108.329 -1.087
201912 -0.620 108.420 -0.740
202003 -0.910 108.902 -1.081
202006 -0.940 108.767 -1.118
202009 -0.660 109.815 -0.778
202012 0.020 109.897 0.024
202103 -0.900 111.754 -1.042
202106 -0.660 114.631 -0.745
202109 -0.860 115.734 -0.962
202112 -0.950 117.630 -1.045
202203 -1.080 121.301 -1.152
202206 -0.670 125.017 -0.694
202209 -0.400 125.227 -0.413
202212 0.210 125.222 0.217
202303 -0.610 127.348 -0.620
202306 0.920 128.729 0.925
202309 0.280 129.860 0.279
202312 -0.750 129.419 -0.750

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Macrogenics  (NAS:MGNX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Macrogenics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Macrogenics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics (Macrogenics) Business Description

Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Executives
Ezio Bonvini officer: Sr VP, Research & CSO 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz director
Jeffrey Stuart Peters officer: Acting General Counsel 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Margaret Liu director C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
James Karrels officer: SVP, CFO and Secretary 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Thomas Spitznagel officer: Sr VP, BPD & Manufacturing 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Eric Blasius Risser officer: Sr VP & Chief Business Officer 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth Galbraith director OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck officer: Chief Medical Officer 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949